At ESMO Congress 2019, one of the Patient Advocacy sessions addressed a key issue in the management of non-small cell lung cancer, i.e. having a common cancer split into different subgroups. With more molecular target being identified, some new challenges have emerged as highlights Dr Enriqueta Felip, from Vall d'Hebron University Hospital, Barcelona, Spain.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.